Amneal Pharmaceuticals, Inc. (AMRX) 10-Year Financial Performance & Capital Metrics

AMRX • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsComplex Generics

AboutAmneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.Show more

Revenue $2.79B +16.7%
EBITDA $486M +11.9%
Net Income -$117M -39.2%
EPS (Diluted) -0.38 +20.8%
Gross Margin 36.52% +1.2%
EBITDA Margin 17.38% -4.1%
Operating Margin 8.92% +4.5%
Net Margin -4.18% -19.2%
ROE -1394.32% -2143.0%
ROIC 7.25% +35.9%
Debt/Equity -
Interest Coverage 0.96 -0.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)
✓Strong 5Y sales CAGR of 11.4%
✓Trading near 52-week high

✗Weaknesses

✗Shares diluted 75.4% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y11.43%

3Y10.1%

TTM9.5%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM103.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM102.14%

ROCE

10Y Avg9.92%

5Y Avg4.33%

3Y Avg4.72%

Latest9.98%

Peer Comparison

Complex Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AMPHAmphastar Pharmaceuticals, Inc.	1.19B	26.00	8.50	13.59%	15.43%	14.37%	14.43%	0.89
AMRXAmneal Pharmaceuticals, Inc.	4.15B	13.19	-34.71	16.73%	0.2%	-13.94%	5.31%
ANIPANI Pharmaceuticals, Inc.	1.92B	85.29	-82.01	26.2%	4.61%	7.53%	2.46%	1.46

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	866.28M	1.02B	1.03B	1.66B	1.63B	1.99B	2.09B	2.21B	2.39B	2.79B
Revenue Growth %	-	0.18%	0.02%	0.61%	-0.02%	0.23%	0.05%	0.06%	0.08%	0.17%
Cost of Goods Sold+	367.05M	420.77M	507.48M	946.59M	1.27B	1.36B	1.32B	1.42B	1.53B	1.77B
COGS % of Revenue	0.42%	0.41%	0.49%	0.57%	0.78%	0.68%	0.63%	0.64%	0.64%	0.63%
Gross Profit+	499.23M	597.46M	526.18M	716.4M	353M	628.39M	768.97M	791.46M	863.87M	1.02B
Gross Margin %	0.58%	0.59%	0.51%	0.43%	0.22%	0.32%	0.37%	0.36%	0.36%	0.37%
Gross Profit Growth %	-	0.2%	-0.12%	0.36%	-0.51%	0.78%	0.22%	0.03%	0.09%	0.18%
Operating Expenses+	277.81M	323.5M	300.98M	440.89M	601.68M	537.24M	616.26M	886.39M	659.5M	771.11M
OpEx % of Revenue	0.32%	0.32%	0.29%	0.27%	0.37%	0.27%	0.29%	0.4%	0.28%	0.28%
Selling, General & Admin	109.68M	118.76M	109.05M	230.44M	289.6M	326.73M	365.5M	399.7M	429.68M	476.44M
SG&A % of Revenue	0.13%	0.12%	0.11%	0.14%	0.18%	0.16%	0.17%	0.18%	0.18%	0.17%
Research & Development	136.87M	204.75M	191.94M	210.45M	202.29M	190.59M	209.56M	208.66M	194.75M	190.71M
R&D % of Revenue	0.16%	0.2%	0.19%	0.13%	0.12%	0.1%	0.1%	0.09%	0.08%	0.07%
Other Operating Expenses	0	-669K	-47K	2.85M	109.79M	19.93M	41.19M	278.03M	35.07M	103.96M
Operating Income+	227.23M	284.88M	245.1M	-19.67M	-248.68M	91.16M	152.72M	-94.93M	204.37M	249.33M
Operating Margin %	0.26%	0.28%	0.24%	-0.01%	-0.15%	0.05%	0.07%	-0.04%	0.09%	0.09%
Operating Income Growth %	-	0.25%	-0.14%	-1.08%	-11.64%	1.37%	0.68%	-1.62%	3.15%	0.22%
EBITDA+	252.68M	317.9M	291.04M	117.73M	-41.45M	326.54M	386.12M	145.25M	433.77M	485.52M
EBITDA Margin %	0.29%	0.31%	0.28%	0.07%	-0.03%	0.16%	0.18%	0.07%	0.18%	0.17%
EBITDA Growth %	-	0.26%	-0.08%	-0.6%	-1.35%	8.88%	0.18%	-0.62%	1.99%	0.12%
D&A (Non-Cash Add-back)	25.45M	33.02M	45.94M	137.4M	207.24M	235.39M	233.41M	240.18M	229.4M	236.19M
EBIT	227.23M	270.1M	242.38M	-59.15M	-52.04M	110.22M	167.69M	200.03M	271.38M	203.58M
Net Interest Income+	0	-55.28M	-71.06M	-143.57M	-168.21M	-146M	-136.32M	-158.67M	-210.63M	-258.6M
Interest Income	45.84M	0	0	0	0	0	0	158.38M	0	0
Interest Expense	0	55.28M	71.06M	143.57M	168.21M	146M	136.32M	158.38M	210.63M	258.6M
Other Income/Expense	-60.58M	-70.06M	-73.78M	-183.05M	28.44M	-126.94M	-121.35M	-153.2M	-244.64M	-304.34M
Pretax Income+	175.58M	214.82M	171.32M	-202.72M	-220.24M	-35.78M	31.37M	-248.13M	-40.27M	-55.01M
Pretax Margin %	0.2%	0.21%	0.17%	-0.12%	-0.14%	-0.02%	0.01%	-0.11%	-0.02%	-0.02%
Income Tax+	4.95M	5.39M	2M	-1.42M	383.33M	-104.36M	11.2M	6.66M	8.45M	18.86M
Effective Tax Rate %	0.97%	0.97%	0.98%	0.84%	1.64%	-2.54%	0.34%	0.52%	2.09%	2.12%
Net Income+	169.45M	207.38M	167.65M	-169.73M	-361.92M	91.06M	10.62M	-129.99M	-83.99M	-116.89M
Net Margin %	0.2%	0.2%	0.16%	-0.1%	-0.22%	0.05%	0.01%	-0.06%	-0.04%	-0.04%
Net Income Growth %	-	0.22%	-0.19%	-2.01%	-1.13%	1.25%	-0.88%	-13.24%	0.35%	-0.39%
Net Income (Continuing)	170.63M	209.43M	169.32M	-201.3M	-603.57M	68.58M	20.17M	-254.79M	-48.72M	-73.88M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	8.27M	9.35M	10.16M	391.61M	114.78M	53.47M	6.63M	-89.49M	41.52M	64.73M
EPS (Diluted)+	0.90	1.10	1.46	-1.33	-4.57	0.61	0.07	-0.86	-0.48	-0.38
EPS Growth %	-	0.22%	0.33%	-1.91%	-2.44%	1.13%	-0.89%	-13.29%	0.44%	0.21%
EPS (Basic)	0.90	1.10	1.46	-1.33	-4.57	0.62	0.07	-0.86	-0.48	-0.38
Diluted Shares Outstanding	189M	189M	114.86M	127.25M	132.11M	148.91M	151.82M	150.94M	176.14M	308.98M
Basic Shares Outstanding	189M	189M	114.86M	127.25M	132.09M	149.28M	148.92M	150.94M	174.99M	308.98M
Dividend Payout Ratio	1.52%	0.97%	2.24%	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	604.6M	726.11M	771.93M	1.29B	1.21B	1.55B	1.52B	1.41B	1.38B	1.59B
Cash & Short-Term Investments	66.06M	31.72M	74.17M	213.39M	152.32M	343.07M	247.79M	27.8M	93.74M	112.42M
Cash Only	61.09M	27.37M	74.17M	213.39M	151.2M	341.38M	247.79M	25.98M	91.54M	110.55M
Short-Term Investments	4.98M	4.35M	0	0	1.12M	1.7M	0	1.82M	2.2M	1.87M
Accounts Receivable	273.83M	394.79M	351.37M	565.32M	604.39M	639M	694.74M	741.79M	645.66M	775.73M
Days Sales Outstanding	115.38	141.52	124.07	124.08	135.64	117.05	121.12	122.39	98.46	101.34
Inventory	234.97M	266.16M	284.04M	457.22M	381.07M	490.65M	489.39M	530.74M	581.38M	612.45M
Days Inventory Outstanding	233.65	230.88	204.29	176.3	109.23	131.28	134.84	136.34	138.72	126.05
Other Current Assets	21.93M	22.74M	35.12M	52.82M	33.13M	40.96M	41.95M	64.37M	7.57M	40.7M
Total Non-Current Assets+	398.34M	481.77M	569.96M	3.07B	2.46B	2.45B	2.42B	2.39B	2.09B	1.91B
Property, Plant & Equipment	318.82M	407.4M	486.76M	544.15M	620.6M	604.71M	639M	589.36M	550.14M	523.69M
Fixed Asset Turnover	2.72x	2.50x	2.12x	3.06x	2.62x	3.30x	3.28x	3.75x	4.35x	5.34x
Goodwill	29.82M	28.44M	26.44M	426.23M	419.5M	522.81M	593.02M	598.85M	598.63M	597.44M
Intangible Assets	49.69M	45.93M	44.6M	1.65B	1.38B	1.3B	1.17B	1.1B	890.42M	732.38M
Long-Term Investments	0	0	0	0	16.37M	0	0	85.59M	37.09M	35.92M
Other Non-Current Assets	-398.34M	-481.77M	11.26M	67.59M	16.45M	22.34M	20.61M	17.63M	18.43M	24.21M
Total Assets+	1.01B	1.22B	1.34B	4.35B	3.67B	4.01B	3.94B	3.8B	3.47B	3.5B
Asset Turnover	0.85x	0.84x	0.77x	0.38x	0.44x	0.50x	0.53x	0.58x	0.69x	0.80x
Asset Growth %	-	0.2%	0.1%	2.24%	-0.16%	0.09%	-0.02%	-0.04%	-0.09%	0.01%
Total Current Liabilities+	239.15M	225.07M	296.88M	553.85M	550.41M	676.9M	677.24M	752.8M	846.6M	1.13B
Accounts Payable	69.93M	60.03M	70.01M	114.85M	103.02M	154.14M	131.08M	166.84M	143.57M	259.84M
Days Payables Outstanding	69.54	52.08	50.36	44.28	29.53	41.24	36.12	42.86	34.26	53.48
Short-Term Debt	59.6M	36.89M	89.17M	21.45M	21.48M	45.23M	30.61M	89.96M	213.13M	324.21M
Deferred Revenue (Current)	0	0	1000K	1000K	0	0	0	0	1000K	0
Other Current Liabilities	48.91M	63.82M	72.2M	200.83M	176.32M	207.31M	120.1M	263.11M	3.91M	222.36M
Current Ratio	2.53x	3.23x	2.60x	2.32x	2.20x	2.29x	2.24x	1.88x	1.63x	1.41x
Quick Ratio	1.55x	2.04x	1.64x	1.50x	1.51x	1.57x	1.52x	1.17x	0.94x	0.86x
Cash Conversion Cycle	279.49	320.32	278.01	256.1	215.34	207.09	219.84	215.87	202.92	173.91
Total Non-Current Liabilities+	951.62M	1.16B	1.42B	2.9B	2.77B	2.97B	2.9B	2.84B	2.56B	2.42B
Long-Term Debt	951.62M	1.16B	1.36B	2.63B	2.61B	2.83B	2.72B	2.63B	2.43B	2.16B
Capital Lease Obligations	1.01M	921K	39.99M	39.08M	123.94M	115.74M	111.93M	108.81M	95.45M	91.09M
Deferred Tax Liabilities	0	0	2.49M	1.18M	0	0	0	0	0	0
Other Non-Current Liabilities	-1.01M	-921K	10.28M	231.66M	35.71M	31.05M	65.43M	97.12M	41.77M	163.33M
Total Liabilities	1.2B	1.39B	1.72B	3.46B	3.32B	3.65B	3.57B	3.59B	3.41B	3.55B
Total Debt+	1.01B	1.2B	1.48B	2.69B	2.77B	3B	2.88B	2.85B	2.75B	2.59B
Net Debt	951.23M	1.17B	1.41B	2.48B	2.62B	2.66B	2.63B	2.82B	2.66B	2.48B
Debt / Equity	-	-	-	2.09x	7.99x	8.41x	7.84x	13.62x	44.87x	-
Debt / EBITDA	4.01x	3.77x	5.10x	22.86x	-	9.18x	7.45x	19.59x	6.34x	5.34x
Net Debt / EBITDA	3.76x	3.68x	4.85x	21.05x	-	8.14x	6.81x	19.41x	6.13x	5.11x
Interest Coverage	-	5.15x	3.45x	-0.14x	-1.48x	0.62x	1.12x	-0.60x	0.97x	0.96x
Total Equity+	-186.87M	-175.94M	-375.58M	1.29B	346.79M	356.74M	366.97M	208.93M	61.3M	-44.54M
Equity Growth %	-	0.06%	-1.13%	4.43%	-0.73%	0.03%	0.03%	-0.43%	-0.71%	-1.73%
Book Value per Share	-0.99	-0.93	-3.27	10.12	2.63	2.40	2.42	1.38	0.35	-0.14
Total Shareholders' Equity	-195.14M	-185.29M	-385.74M	896.36M	232.01M	303.27M	360.34M	298.42M	19.78M	-109.27M
Common Stock	2.67M	2.67M	2.72M	2.99M	2.99M	3M	3.01M	3.04M	3.07M	3.1M
Retained Earnings	-181.97M	-175.17M	-382.79M	-20.92M	-377.88M	-286.82M	-276.2M	-406.18M	-490.18M	-607.06M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	-14.23M	-7.75M	-68K	-41.32M	-24.83M	9.94M	-32.35M	-65.51M
Minority Interest	8.27M	9.35M	10.16M	391.61M	114.78M	53.47M	6.63M	-89.49M	41.52M	64.73M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	104.88M	115.06M	234.19M	250.23M	1.71M	379M	241.82M	65.1M	345.58M	295.1M
Operating CF Margin %	0.12%	0.11%	0.23%	0.15%	0%	0.19%	0.12%	0.03%	0.14%	0.11%
Operating CF Growth %	-	0.1%	1.04%	0.07%	-0.99%	221.29%	-0.36%	-0.73%	4.31%	-0.15%
Net Income	169.45M	209.43M	169.32M	-201.3M	-603.57M	91.06M	10.62M	-254.79M	-48.72M	-73.88M
Depreciation & Amortization	25.45M	33.02M	45.94M	137.4M	207.24M	244.06M	233.41M	240.18M	229.4M	236.19M
Stock-Based Compensation	0	0	0	167.6M	21.68M	20.75M	0	31.85M	26.82M	27.77M
Deferred Taxes	0	121K	742K	-9.44M	371.72M	0	0	0	0	0
Other Non-Cash Items	-90.02M	3.25M	14.52M	148.96M	124.86M	84.75M	131.38M	107.81M	185.26M	109.08M
Working Capital Changes	-122.73M	-152.15M	-1.05M	7.01M	-120.22M	-61.63M	-133.59M	-59.95M	-47.19M	-4.07M
Change in Receivables	-44.65M	-122.48M	35.26M	89.08M	-133.66M	16.79M	-16.31M	-79.07M	125.8M	-162.16M
Change in Inventory	-78.08M	-42.59M	-31.83M	-42.88M	-20.39M	-113.78M	-49.02M	-102.4M	-126.18M	-130.53M
Change in Payables	0	6.26M	18.11M	-55.21M	-10.26M	0	-43.93M	109.57M	-94.45M	235.13M
Cash from Investing+	-135.62M	-124.61M	-98.55M	-396.38M	-19.58M	-317.55M	-194.18M	-174.31M	-69.19M	-63M
Capital Expenditures	-117.38M	-124.61M	-114.27M	-97.09M	-47.18M	-61.84M	-49.43M	-48.8M	-46.8M	-60.34M
CapEx % of Revenue	0.14%	0.12%	0.11%	0.06%	0.03%	0.03%	0.02%	0.02%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-18.24M	-1.85M	-3.78M	25.34M	-7.23M	-4.35M	-3.21M	-40.8M	-22.39M	-14.65M
Cash from Financing+	-24.99M	-19.5M	-95.02M	287.68M	-45.83M	131.81M	-138.12M	-106.62M	-212.57M	-211.79M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-258.17M	-200.62M	-375.26M	-183M	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	46.19M	-7.48M	-5.85M	-70.37M	-16.56M	-10.32M	-59.8M	-68.35M	-235.22M	-26.67M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.5M	-9.55M	119.92M	153.14M	-95.73M	317.16M	194.09M	-25.5M	276.39M	220.11M
FCF Margin %	-0.01%	-0.01%	0.12%	0.09%	-0.06%	0.16%	0.09%	-0.01%	0.12%	0.08%
FCF Growth %	-	0.24%	13.56%	0.28%	-1.63%	4.31%	-0.39%	-1.13%	11.84%	-0.2%
FCF per Share	-0.07	-0.05	1.04	1.20	-0.72	2.13	1.28	-0.17	1.57	0.71
FCF Conversion (FCF/Net Income)	0.62x	0.55x	1.40x	-1.47x	-0.00x	4.16x	22.76x	-0.50x	-4.11x	-2.52x
Interest Paid	0	0	0	131.5M	158.57M	130.19M	0	142.72M	192.81M	263.52M
Taxes Paid	0	0	0	34.95M	10.26M	0	0	12.65M	2.5M	15.22M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-37.2%	-44.28%	25.89%	2.94%	-45.14%	-62.16%	-1394.32%
Return on Invested Capital (ROIC)	22.3%	24.3%	18.12%	-0.61%	-5.54%	2.29%	3.81%	-2.36%	5.33%	7.25%
Gross Margin	57.63%	58.68%	50.9%	43.08%	21.7%	31.54%	36.73%	35.78%	36.09%	36.52%
Net Margin	19.56%	20.37%	16.22%	-10.21%	-22.25%	4.57%	0.51%	-5.88%	-3.51%	-4.18%
Debt / Equity	-	-	-	2.09x	7.99x	8.41x	7.84x	13.62x	44.87x	-
Interest Coverage	-	5.15x	3.45x	-0.14x	-1.48x	0.62x	1.12x	-0.60x	0.97x	0.96x
FCF Conversion	0.62x	0.55x	1.40x	-1.47x	-0.00x	4.16x	22.76x	-0.50x	-4.11x	-2.52x
Revenue Growth	-	17.54%	1.52%	60.88%	-2.2%	22.51%	5.08%	5.67%	8.2%	16.73%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Specialty	-	317.53M	-	-	-	390.46M	445.75M
Specialty Growth	-	-	-	-	-	-	14.16%
Generics	-	1.29B	1.34B	1.37B	1.43B	1.47B	-
Generics Growth	-	-	4.50%	1.72%	4.81%	2.75%	-
Av K A R E	-	-	-	-	406.11M	-	-
Av K A R E Growth	-	-	-	-	-	-	-
Amneal Specialty Pharma	-	-	355.57M	378.32M	374.12M	-	-
Amneal Specialty Pharma Growth	-	-	-	6.40%	-1.11%	-	-
Av Kare	-	-	293.75M	349.01M	-	-	-
Av Kare Growth	-	-	-	18.81%	-	-	-
Yuvafem-Estradiol	130.92M	-	-	-	-	-	-
Yuvafem-Estradiol Growth	-	-	-	-	-	-	-
Diclofenac Sodium Gel	103.13M	-	-	-	-	-	-
Diclofenac Sodium Gel Growth	-	-	-	-	-	-	-
Rytary Family	95.54M	-	-	-	-	-	-
Rytary Family Growth	-	-	-	-	-	-	-
Aspirin;Dipyridamole ER Capsul	78.54M	-	-	-	-	-	-
Aspirin;Dipyridamole ER Capsul Growth	-	-	-	-	-	-	-
Epinephrine Auto-Injector Family (Generic Adrenaclick)	67.53M	-	-	-	-	-	-
Epinephrine Auto-Injector Family (Generic Adrenaclick) Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Amneal Pharmaceuticals, Inc. (AMRX) reported $2.93B in revenue for fiscal year 2024. This represents a 239% increase from $866.3M in 2015.

Amneal Pharmaceuticals, Inc. (AMRX) grew revenue by 16.7% over the past year. This is strong growth.

Yes, Amneal Pharmaceuticals, Inc. (AMRX) is profitable, generating $5.9M in net income for fiscal year 2024 (-4.2% net margin).

Dividend & Returns

Amneal Pharmaceuticals, Inc. (AMRX) has a return on equity (ROE) of -1394.3%. Negative ROE indicates the company is unprofitable.

Amneal Pharmaceuticals, Inc. (AMRX) generated $244.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Amneal Pharmaceuticals, Inc. (AMRX) 10-Year Financial Performance & Capital Metrics

AMRX • • Industrial / General

HealthcareSpecialty & Generic PharmaGeneric PharmaceuticalsComplex Generics

Revenue $2.79B +16.7%
EBITDA $486M +11.9%
Net Income -$117M -39.2%
EPS (Diluted) -0.38 +20.8%
Gross Margin 36.52% +1.2%
EBITDA Margin 17.38% -4.1%
Operating Margin 8.92% +4.5%
Net Margin -4.18% -19.2%
ROE -1394.32% -2143.0%
ROIC 7.25% +35.9%
Debt/Equity -
Interest Coverage 0.96 -0.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 84 (top 16%)
✓Strong 5Y sales CAGR of 11.4%
✓Trading near 52-week high

✗Weaknesses

✗Shares diluted 75.4% in last year

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y11.43%

3Y10.1%

TTM9.5%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM103.2%

EPS CAGR

10Y-

5Y-

3Y-

TTM102.14%

ROCE

10Y Avg9.92%

5Y Avg4.33%

3Y Avg4.72%

Latest9.98%

Peer Comparison

Complex Generics

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AMPHAmphastar Pharmaceuticals, Inc.	1.19B	26.00	8.50	13.59%	15.43%	14.37%	14.43%	0.89
AMRXAmneal Pharmaceuticals, Inc.	4.15B	13.19	-34.71	16.73%	0.2%	-13.94%	5.31%
ANIPANI Pharmaceuticals, Inc.	1.92B	85.29	-82.01	26.2%	4.61%	7.53%	2.46%	1.46

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	866.28M	1.02B	1.03B	1.66B	1.63B	1.99B	2.09B	2.21B	2.39B	2.79B
Revenue Growth %	-	0.18%	0.02%	0.61%	-0.02%	0.23%	0.05%	0.06%	0.08%	0.17%
Cost of Goods Sold+	367.05M	420.77M	507.48M	946.59M	1.27B	1.36B	1.32B	1.42B	1.53B	1.77B
COGS % of Revenue	0.42%	0.41%	0.49%	0.57%	0.78%	0.68%	0.63%	0.64%	0.64%	0.63%
Gross Profit+	499.23M	597.46M	526.18M	716.4M	353M	628.39M	768.97M	791.46M	863.87M	1.02B
Gross Margin %	0.58%	0.59%	0.51%	0.43%	0.22%	0.32%	0.37%	0.36%	0.36%	0.37%
Gross Profit Growth %	-	0.2%	-0.12%	0.36%	-0.51%	0.78%	0.22%	0.03%	0.09%	0.18%
Operating Expenses+	277.81M	323.5M	300.98M	440.89M	601.68M	537.24M	616.26M	886.39M	659.5M	771.11M
OpEx % of Revenue	0.32%	0.32%	0.29%	0.27%	0.37%	0.27%	0.29%	0.4%	0.28%	0.28%
Selling, General & Admin	109.68M	118.76M	109.05M	230.44M	289.6M	326.73M	365.5M	399.7M	429.68M	476.44M
SG&A % of Revenue	0.13%	0.12%	0.11%	0.14%	0.18%	0.16%	0.17%	0.18%	0.18%	0.17%
Research & Development	136.87M	204.75M	191.94M	210.45M	202.29M	190.59M	209.56M	208.66M	194.75M	190.71M
R&D % of Revenue	0.16%	0.2%	0.19%	0.13%	0.12%	0.1%	0.1%	0.09%	0.08%	0.07%
Other Operating Expenses	0	-669K	-47K	2.85M	109.79M	19.93M	41.19M	278.03M	35.07M	103.96M
Operating Income+	227.23M	284.88M	245.1M	-19.67M	-248.68M	91.16M	152.72M	-94.93M	204.37M	249.33M
Operating Margin %	0.26%	0.28%	0.24%	-0.01%	-0.15%	0.05%	0.07%	-0.04%	0.09%	0.09%
Operating Income Growth %	-	0.25%	-0.14%	-1.08%	-11.64%	1.37%	0.68%	-1.62%	3.15%	0.22%
EBITDA+	252.68M	317.9M	291.04M	117.73M	-41.45M	326.54M	386.12M	145.25M	433.77M	485.52M
EBITDA Margin %	0.29%	0.31%	0.28%	0.07%	-0.03%	0.16%	0.18%	0.07%	0.18%	0.17%
EBITDA Growth %	-	0.26%	-0.08%	-0.6%	-1.35%	8.88%	0.18%	-0.62%	1.99%	0.12%
D&A (Non-Cash Add-back)	25.45M	33.02M	45.94M	137.4M	207.24M	235.39M	233.41M	240.18M	229.4M	236.19M
EBIT	227.23M	270.1M	242.38M	-59.15M	-52.04M	110.22M	167.69M	200.03M	271.38M	203.58M
Net Interest Income+	0	-55.28M	-71.06M	-143.57M	-168.21M	-146M	-136.32M	-158.67M	-210.63M	-258.6M
Interest Income	45.84M	0	0	0	0	0	0	158.38M	0	0
Interest Expense	0	55.28M	71.06M	143.57M	168.21M	146M	136.32M	158.38M	210.63M	258.6M
Other Income/Expense	-60.58M	-70.06M	-73.78M	-183.05M	28.44M	-126.94M	-121.35M	-153.2M	-244.64M	-304.34M
Pretax Income+	175.58M	214.82M	171.32M	-202.72M	-220.24M	-35.78M	31.37M	-248.13M	-40.27M	-55.01M
Pretax Margin %	0.2%	0.21%	0.17%	-0.12%	-0.14%	-0.02%	0.01%	-0.11%	-0.02%	-0.02%
Income Tax+	4.95M	5.39M	2M	-1.42M	383.33M	-104.36M	11.2M	6.66M	8.45M	18.86M
Effective Tax Rate %	0.97%	0.97%	0.98%	0.84%	1.64%	-2.54%	0.34%	0.52%	2.09%	2.12%
Net Income+	169.45M	207.38M	167.65M	-169.73M	-361.92M	91.06M	10.62M	-129.99M	-83.99M	-116.89M
Net Margin %	0.2%	0.2%	0.16%	-0.1%	-0.22%	0.05%	0.01%	-0.06%	-0.04%	-0.04%
Net Income Growth %	-	0.22%	-0.19%	-2.01%	-1.13%	1.25%	-0.88%	-13.24%	0.35%	-0.39%
Net Income (Continuing)	170.63M	209.43M	169.32M	-201.3M	-603.57M	68.58M	20.17M	-254.79M	-48.72M	-73.88M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	8.27M	9.35M	10.16M	391.61M	114.78M	53.47M	6.63M	-89.49M	41.52M	64.73M
EPS (Diluted)+	0.90	1.10	1.46	-1.33	-4.57	0.61	0.07	-0.86	-0.48	-0.38
EPS Growth %	-	0.22%	0.33%	-1.91%	-2.44%	1.13%	-0.89%	-13.29%	0.44%	0.21%
EPS (Basic)	0.90	1.10	1.46	-1.33	-4.57	0.62	0.07	-0.86	-0.48	-0.38
Diluted Shares Outstanding	189M	189M	114.86M	127.25M	132.11M	148.91M	151.82M	150.94M	176.14M	308.98M
Basic Shares Outstanding	189M	189M	114.86M	127.25M	132.09M	149.28M	148.92M	150.94M	174.99M	308.98M
Dividend Payout Ratio	1.52%	0.97%	2.24%	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	604.6M	726.11M	771.93M	1.29B	1.21B	1.55B	1.52B	1.41B	1.38B	1.59B
Cash & Short-Term Investments	66.06M	31.72M	74.17M	213.39M	152.32M	343.07M	247.79M	27.8M	93.74M	112.42M
Cash Only	61.09M	27.37M	74.17M	213.39M	151.2M	341.38M	247.79M	25.98M	91.54M	110.55M
Short-Term Investments	4.98M	4.35M	0	0	1.12M	1.7M	0	1.82M	2.2M	1.87M
Accounts Receivable	273.83M	394.79M	351.37M	565.32M	604.39M	639M	694.74M	741.79M	645.66M	775.73M
Days Sales Outstanding	115.38	141.52	124.07	124.08	135.64	117.05	121.12	122.39	98.46	101.34
Inventory	234.97M	266.16M	284.04M	457.22M	381.07M	490.65M	489.39M	530.74M	581.38M	612.45M
Days Inventory Outstanding	233.65	230.88	204.29	176.3	109.23	131.28	134.84	136.34	138.72	126.05
Other Current Assets	21.93M	22.74M	35.12M	52.82M	33.13M	40.96M	41.95M	64.37M	7.57M	40.7M
Total Non-Current Assets+	398.34M	481.77M	569.96M	3.07B	2.46B	2.45B	2.42B	2.39B	2.09B	1.91B
Property, Plant & Equipment	318.82M	407.4M	486.76M	544.15M	620.6M	604.71M	639M	589.36M	550.14M	523.69M
Fixed Asset Turnover	2.72x	2.50x	2.12x	3.06x	2.62x	3.30x	3.28x	3.75x	4.35x	5.34x
Goodwill	29.82M	28.44M	26.44M	426.23M	419.5M	522.81M	593.02M	598.85M	598.63M	597.44M
Intangible Assets	49.69M	45.93M	44.6M	1.65B	1.38B	1.3B	1.17B	1.1B	890.42M	732.38M
Long-Term Investments	0	0	0	0	16.37M	0	0	85.59M	37.09M	35.92M
Other Non-Current Assets	-398.34M	-481.77M	11.26M	67.59M	16.45M	22.34M	20.61M	17.63M	18.43M	24.21M
Total Assets+	1.01B	1.22B	1.34B	4.35B	3.67B	4.01B	3.94B	3.8B	3.47B	3.5B
Asset Turnover	0.85x	0.84x	0.77x	0.38x	0.44x	0.50x	0.53x	0.58x	0.69x	0.80x
Asset Growth %	-	0.2%	0.1%	2.24%	-0.16%	0.09%	-0.02%	-0.04%	-0.09%	0.01%
Total Current Liabilities+	239.15M	225.07M	296.88M	553.85M	550.41M	676.9M	677.24M	752.8M	846.6M	1.13B
Accounts Payable	69.93M	60.03M	70.01M	114.85M	103.02M	154.14M	131.08M	166.84M	143.57M	259.84M
Days Payables Outstanding	69.54	52.08	50.36	44.28	29.53	41.24	36.12	42.86	34.26	53.48
Short-Term Debt	59.6M	36.89M	89.17M	21.45M	21.48M	45.23M	30.61M	89.96M	213.13M	324.21M
Deferred Revenue (Current)	0	0	1000K	1000K	0	0	0	0	1000K	0
Other Current Liabilities	48.91M	63.82M	72.2M	200.83M	176.32M	207.31M	120.1M	263.11M	3.91M	222.36M
Current Ratio	2.53x	3.23x	2.60x	2.32x	2.20x	2.29x	2.24x	1.88x	1.63x	1.41x
Quick Ratio	1.55x	2.04x	1.64x	1.50x	1.51x	1.57x	1.52x	1.17x	0.94x	0.86x
Cash Conversion Cycle	279.49	320.32	278.01	256.1	215.34	207.09	219.84	215.87	202.92	173.91
Total Non-Current Liabilities+	951.62M	1.16B	1.42B	2.9B	2.77B	2.97B	2.9B	2.84B	2.56B	2.42B
Long-Term Debt	951.62M	1.16B	1.36B	2.63B	2.61B	2.83B	2.72B	2.63B	2.43B	2.16B
Capital Lease Obligations	1.01M	921K	39.99M	39.08M	123.94M	115.74M	111.93M	108.81M	95.45M	91.09M
Deferred Tax Liabilities	0	0	2.49M	1.18M	0	0	0	0	0	0
Other Non-Current Liabilities	-1.01M	-921K	10.28M	231.66M	35.71M	31.05M	65.43M	97.12M	41.77M	163.33M
Total Liabilities	1.2B	1.39B	1.72B	3.46B	3.32B	3.65B	3.57B	3.59B	3.41B	3.55B
Total Debt+	1.01B	1.2B	1.48B	2.69B	2.77B	3B	2.88B	2.85B	2.75B	2.59B
Net Debt	951.23M	1.17B	1.41B	2.48B	2.62B	2.66B	2.63B	2.82B	2.66B	2.48B
Debt / Equity	-	-	-	2.09x	7.99x	8.41x	7.84x	13.62x	44.87x	-
Debt / EBITDA	4.01x	3.77x	5.10x	22.86x	-	9.18x	7.45x	19.59x	6.34x	5.34x
Net Debt / EBITDA	3.76x	3.68x	4.85x	21.05x	-	8.14x	6.81x	19.41x	6.13x	5.11x
Interest Coverage	-	5.15x	3.45x	-0.14x	-1.48x	0.62x	1.12x	-0.60x	0.97x	0.96x
Total Equity+	-186.87M	-175.94M	-375.58M	1.29B	346.79M	356.74M	366.97M	208.93M	61.3M	-44.54M
Equity Growth %	-	0.06%	-1.13%	4.43%	-0.73%	0.03%	0.03%	-0.43%	-0.71%	-1.73%
Book Value per Share	-0.99	-0.93	-3.27	10.12	2.63	2.40	2.42	1.38	0.35	-0.14
Total Shareholders' Equity	-195.14M	-185.29M	-385.74M	896.36M	232.01M	303.27M	360.34M	298.42M	19.78M	-109.27M
Common Stock	2.67M	2.67M	2.72M	2.99M	2.99M	3M	3.01M	3.04M	3.07M	3.1M
Retained Earnings	-181.97M	-175.17M	-382.79M	-20.92M	-377.88M	-286.82M	-276.2M	-406.18M	-490.18M	-607.06M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	-14.23M	-7.75M	-68K	-41.32M	-24.83M	9.94M	-32.35M	-65.51M
Minority Interest	8.27M	9.35M	10.16M	391.61M	114.78M	53.47M	6.63M	-89.49M	41.52M	64.73M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	104.88M	115.06M	234.19M	250.23M	1.71M	379M	241.82M	65.1M	345.58M	295.1M
Operating CF Margin %	0.12%	0.11%	0.23%	0.15%	0%	0.19%	0.12%	0.03%	0.14%	0.11%
Operating CF Growth %	-	0.1%	1.04%	0.07%	-0.99%	221.29%	-0.36%	-0.73%	4.31%	-0.15%
Net Income	169.45M	209.43M	169.32M	-201.3M	-603.57M	91.06M	10.62M	-254.79M	-48.72M	-73.88M
Depreciation & Amortization	25.45M	33.02M	45.94M	137.4M	207.24M	244.06M	233.41M	240.18M	229.4M	236.19M
Stock-Based Compensation	0	0	0	167.6M	21.68M	20.75M	0	31.85M	26.82M	27.77M
Deferred Taxes	0	121K	742K	-9.44M	371.72M	0	0	0	0	0
Other Non-Cash Items	-90.02M	3.25M	14.52M	148.96M	124.86M	84.75M	131.38M	107.81M	185.26M	109.08M
Working Capital Changes	-122.73M	-152.15M	-1.05M	7.01M	-120.22M	-61.63M	-133.59M	-59.95M	-47.19M	-4.07M
Change in Receivables	-44.65M	-122.48M	35.26M	89.08M	-133.66M	16.79M	-16.31M	-79.07M	125.8M	-162.16M
Change in Inventory	-78.08M	-42.59M	-31.83M	-42.88M	-20.39M	-113.78M	-49.02M	-102.4M	-126.18M	-130.53M
Change in Payables	0	6.26M	18.11M	-55.21M	-10.26M	0	-43.93M	109.57M	-94.45M	235.13M
Cash from Investing+	-135.62M	-124.61M	-98.55M	-396.38M	-19.58M	-317.55M	-194.18M	-174.31M	-69.19M	-63M
Capital Expenditures	-117.38M	-124.61M	-114.27M	-97.09M	-47.18M	-61.84M	-49.43M	-48.8M	-46.8M	-60.34M
CapEx % of Revenue	0.14%	0.12%	0.11%	0.06%	0.03%	0.03%	0.02%	0.02%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-18.24M	-1.85M	-3.78M	25.34M	-7.23M	-4.35M	-3.21M	-40.8M	-22.39M	-14.65M
Cash from Financing+	-24.99M	-19.5M	-95.02M	287.68M	-45.83M	131.81M	-138.12M	-106.62M	-212.57M	-211.79M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-258.17M	-200.62M	-375.26M	-183M	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	46.19M	-7.48M	-5.85M	-70.37M	-16.56M	-10.32M	-59.8M	-68.35M	-235.22M	-26.67M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-12.5M	-9.55M	119.92M	153.14M	-95.73M	317.16M	194.09M	-25.5M	276.39M	220.11M
FCF Margin %	-0.01%	-0.01%	0.12%	0.09%	-0.06%	0.16%	0.09%	-0.01%	0.12%	0.08%
FCF Growth %	-	0.24%	13.56%	0.28%	-1.63%	4.31%	-0.39%	-1.13%	11.84%	-0.2%
FCF per Share	-0.07	-0.05	1.04	1.20	-0.72	2.13	1.28	-0.17	1.57	0.71
FCF Conversion (FCF/Net Income)	0.62x	0.55x	1.40x	-1.47x	-0.00x	4.16x	22.76x	-0.50x	-4.11x	-2.52x
Interest Paid	0	0	0	131.5M	158.57M	130.19M	0	142.72M	192.81M	263.52M
Taxes Paid	0	0	0	34.95M	10.26M	0	0	12.65M	2.5M	15.22M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-	-37.2%	-44.28%	25.89%	2.94%	-45.14%	-62.16%	-1394.32%
Return on Invested Capital (ROIC)	22.3%	24.3%	18.12%	-0.61%	-5.54%	2.29%	3.81%	-2.36%	5.33%	7.25%
Gross Margin	57.63%	58.68%	50.9%	43.08%	21.7%	31.54%	36.73%	35.78%	36.09%	36.52%
Net Margin	19.56%	20.37%	16.22%	-10.21%	-22.25%	4.57%	0.51%	-5.88%	-3.51%	-4.18%
Debt / Equity	-	-	-	2.09x	7.99x	8.41x	7.84x	13.62x	44.87x	-
Interest Coverage	-	5.15x	3.45x	-0.14x	-1.48x	0.62x	1.12x	-0.60x	0.97x	0.96x
FCF Conversion	0.62x	0.55x	1.40x	-1.47x	-0.00x	4.16x	22.76x	-0.50x	-4.11x	-2.52x
Revenue Growth	-	17.54%	1.52%	60.88%	-2.2%	22.51%	5.08%	5.67%	8.2%	16.73%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Specialty	-	317.53M	-	-	-	390.46M	445.75M
Specialty Growth	-	-	-	-	-	-	14.16%
Generics	-	1.29B	1.34B	1.37B	1.43B	1.47B	-
Generics Growth	-	-	4.50%	1.72%	4.81%	2.75%	-
Av K A R E	-	-	-	-	406.11M	-	-
Av K A R E Growth	-	-	-	-	-	-	-
Amneal Specialty Pharma	-	-	355.57M	378.32M	374.12M	-	-
Amneal Specialty Pharma Growth	-	-	-	6.40%	-1.11%	-	-
Av Kare	-	-	293.75M	349.01M	-	-	-
Av Kare Growth	-	-	-	18.81%	-	-	-
Yuvafem-Estradiol	130.92M	-	-	-	-	-	-
Yuvafem-Estradiol Growth	-	-	-	-	-	-	-
Diclofenac Sodium Gel	103.13M	-	-	-	-	-	-
Diclofenac Sodium Gel Growth	-	-	-	-	-	-	-
Rytary Family	95.54M	-	-	-	-	-	-
Rytary Family Growth	-	-	-	-	-	-	-
Aspirin;Dipyridamole ER Capsul	78.54M	-	-	-	-	-	-
Aspirin;Dipyridamole ER Capsul Growth	-	-	-	-	-	-	-
Epinephrine Auto-Injector Family (Generic Adrenaclick)	67.53M	-	-	-	-	-	-
Epinephrine Auto-Injector Family (Generic Adrenaclick) Growth	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

Amneal Pharmaceuticals, Inc. (AMRX) reported $2.93B in revenue for fiscal year 2024. This represents a 239% increase from $866.3M in 2015.

Amneal Pharmaceuticals, Inc. (AMRX) grew revenue by 16.7% over the past year. This is strong growth.

Yes, Amneal Pharmaceuticals, Inc. (AMRX) is profitable, generating $5.9M in net income for fiscal year 2024 (-4.2% net margin).

Dividend & Returns

Amneal Pharmaceuticals, Inc. (AMRX) has a return on equity (ROE) of -1394.3%. Negative ROE indicates the company is unprofitable.

Amneal Pharmaceuticals, Inc. (AMRX) generated $244.8M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.